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108 lung cancer patients (stage IIIb-IV) were included. 55/108 had 
abnormal bone scan and received BPs (Group A)-zoledronic acid, 8 mg 
i.v. every 21 days- whereas the other 53 patients didn’t receive BPs: 
30/53 with abnormal bone scan (Group B) and 23/53 patients with nor-
mal bone scan (Group C-control group). All patients were treated with 
a combination chemotherapy consisted of taxan plus carboplatin.
Statistical results are shown in the Table below. Compared to Group 
C, Group A had a statistically signiﬁcant longer survival (p=0.015), 
whereas Group B didn’t show any statistical signiﬁcant difference 
in survival compared to Group C (p>0.05). A statistically signiﬁcant 
positive correlation was found between the number of cycles of therapy 
with BPs and total patients’ survival (p<0.01 Pearson correlation) and 
time to progression(p<0.01). Pain effect of BPs didn’t differ signiﬁcant-
ly in both groups of patients with abnormal bone scan (p>0.05).
 Median-Std Error for Survival Time
Group A 433 ± 78
Group B 252 ± 78
Group C 255 ± 87
p 0.004
The addition of BPs seems to increase overall survival in lung cancer 
patients with bone metastases. The longer period of receiving BPs, the 
better effect on survival and time to progression. Further studies are 
needed to support the potential usefulness of BPs as a therapeutic agent 
against lung cancer.
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Background: The multitargeted antifolate and potent TS inhibitor 
pemetrexed compared favorably (similar efﬁcacy, lower toxicity) to 
docetaxel in a large, randomized phase III trial of previously treated 
patients with NSCLC. Preclinical data indicate that overexpression of 
TS correlates with reduced sensitivity to pemetrexed in antifolate-resis-
tant cell lines. A recent study on chemonaive NSCLC patients indicated 
higher TS expression in squamous cell carcinoma than in adenocarci-
noma. These data suggest that patients with adenocarcinoma may have 
greater sensitivity to pemetrexed compared to patients with squamous 
histology. A study to evaluate TS expression in large cell histology is 
currently being planned.  
Methods: This is a retrospective analysis of the large phase III study 
of pemetrexed (500 mg/m2 IV with vitamin B12 injections + oral folic 
acid) vs docetaxel (75 mg/m2 IV) Q 21 days. A statistical test for treat-
ment-by-histology interaction was performed using a Cox model of 
overall survival (OS) with main effects for treatment (pemetrexed vs 
docetaxel) and squamous histology (no vs yes) plus a treatment-by-his-
tology interaction term (non-squamous pemetrexed vs all other). Since 
a potential for imbalances between arms with respect to prognostic 
factors within histologic groups existed, the models were cofactor-
adjusted by including terms for ECOG performance status (PS 0-1 vs 
2), time since prior chemotherapy (≥3 months vs < 3 months), disease 
stage (IIIB vs IV), and gender (female vs male). Subsequent Cox 
models of OS provided estimates of cofactor-adjusted treatment hazard 
ratios (HR) within histologic subgroups. Unadjusted medians within 
histologic subgroups were calculated using the Kaplan-Meier method.    
Results: Treatment-by-histology interaction was statistically signiﬁcant 
(p=.001), indicating that the effect of study treatment on survival varied 
with histology. Medians and hazard ratios by subgroup are presented 
in the table below. In the squamous cell subgroup, patients treated with 
docetaxel had statistically better survival than patients treated with 
pemetrexed (p=.018). However, for each of the non-squamous histolog-
ic subgroups the adjusted HRs numerically favored pemetrexed. When 
combining these into a single non-squamous subgroup, pemetrexed was 
statistically superior to docetaxel (p=.048). 
Histologic Subgroup N Median OS, months Adjusted HR (95% CI)
Squamous Cell:
pemetrexed 78 6.2
docetaxel 94 7.4 1.563 (1.079, 2.264)
Adenocarcinoma:
pemetrexed 158 9.0
docetaxel 144 9.2 0.915 (0.685, 1.224)
Large Cell:
pemetrexed 18 12.8
docetaxel 29 4.5 0.266 (0.112, 0.633)
Other/Indeterminate Histology:
pemetrexed 29 9.4
docetaxel 21 7.9 0.570 (0.270, 1.204)
Combined Non-Squamous:
pemetrexed 205 9.3
docetaxel 194 8.0 0.778 (0.607, 0.997)
Conclusions: The statistically signiﬁcant treatment-by-histology inter-
action indicates that patients with non-squamous histology treated with 
pemetrexed had signiﬁcantly higher survival compared to all others 
on trial. Docetaxel had statistically better survival than pemetrexed in 
the squamous cell subgroup, while pemetrexed had statistically better 
survival than docetaxel in the combined non-squamous subgroup. One 
hypothesis for this observed interaction is that TS overexpression in 
squamous cell carcinoma leads to reduced sens
